Lab eN2

Lab eN² is a drug discovery collaboration between Novo Nordisk, Evotec, and several academic institutions.

The indications of interest are chronic diseases in the cardiometabolic space, with an openness to explore any modality.

Projects are selected on a rolling basis, with the first step being an internal discussion followed by a non-confidential call with the scientific liaison from Evotec.